Systemic treatment of metastatic hormone-sensitive prostate cancer-upfront triplet versus doublet combination therapy

Oing, C.; Bristow, Robert G

dc.contributor.author	Oing, C.
dc.contributor.author	Bristow, Robert G
dc.date.accessioned	2023-04-19T09:32:42Z
dc.date.available	2023-04-19T09:32:42Z
dc.date.issued	2023	en
dc.identifier.citation	Oing C, Bristow RG. Systemic treatment of metastatic hormone-sensitive prostate cancer-upfront triplet versus doublet combination therapy. ESMO open. 2023 Mar 20;8(2):101194. PubMed PMID: 36947986. Pubmed Central PMCID: PMC10040503 Pharmaceuticals; speaker’s honoraria and/or advisory board participation: AstraZeneca, Ipsen, Roche, Sandoz; research funding: PharmaMar (non-financial), all outside the submitted work. RGB has declared no conflicts of interest. Epub 2023/03/23. eng.	en
dc.identifier.pmid	36947986	en
dc.identifier.doi	10.1016/j.esmoop.2023.101194	en
dc.identifier.uri	http://hdl.handle.net/10541/626172
dc.language.iso	en	en
dc.relation.url	https://dx.doi.org/10.1016/j.esmoop.2023.101194	en
dc.title	Systemic treatment of metastatic hormone-sensitive prostate cancer-upfront triplet versus doublet combination therapy	en
dc.type	Other	en
dc.contributor.department	Translational and Clinical Research Institute, Centre for Cancer, Newcastle University, Newcastle upon Tyne, UK	en
dc.identifier.journal	ESMO Open	en
dc.description.note		en]
refterms.dateFOA	2023-04-19T12:42:20Z